Toward Understanding Islet Biology
joint with Pancreatic Islets: From Development to Transplantation
Organizer(s): Lydia Aguilar-Bryan, Bo Ahrén and Christopher B. NewgardDate: February 23 - 28, 2006
Location: Sagebrush Inn & Suites, Taos, NM, USA
The past decade has seen a burgeoning of interest in the biology of the pancreatic islets of Langerhans. The surge in activity is driven in large measure by the rapid increase in the incidence of diabetes, and the critical role of failure of the insulin secreting cells (beta-cells) within the pancreatic islets in the pathogenesis of both major forms of the disease. This symposium will focus specifically on mechanisms of beta-cell failure in type 2 diabetes, which is fast becoming an epidemic disease world-wide (estimated prevalence in the United States alone, 18 million people). Beta-cell failure is now recognized as the event that triggers the transition from pre-diabetes/metabolic syndrome to full-blown type 2 diabetes. Major advances have occurred in our understanding of fundamental beta-cell biology, mechanisms of loss of function and loss of beta-cell mass in type 2 diabetes, and development of new strategies for enhancing beta-cell survival and function in diabetic animals and humans. These advances deserve careful review and discussion in the form of a Keystone symposium to which we expect to attract the very best scientists in the field. These recent advances in knowledge have occurred based on contributions of academic and industrial contributors alike, and our meeting includes invitations to key contributors from both sectors. The meeting will be divided into three major sections: A) Review of recent progress in understanding basic beta-cell biology, including mechanisms of fuel-stimulated insulin secretion and the role of receptor-mediated processes in potentiation of fuel-driven responses; B) Mechanisms of beta-cell dysfunction and destruction in response to metabolic fuel imbalance, including the roles of hyperlipidemia, hyperglycemia, and stress responses; C) Targets for improvement of beta cell function and new technological approaches. In sum, we believe that this program will be a timely and valuable contributor to advancement of a research field that is just beginning to achieve peak visibility and medical relevance.
Scholarship Deadline: October 24 2005
Discounted Abstract Deadline: October 24 2005
Abstract Deadline: November 16 2005
Discounted Registration Deadline: December 23 2005
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Hoffmann-La Roche, Inc.
Merck Research Laboratories